Unknown

Dataset Information

0

Biological and Computational Studies for Dual Cholinesterases Inhibitory Effect of Zerumbone.


ABSTRACT: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) mediate the degradation of acetylcholine (ACh), a primary neurotransmitter in the brain. Cholinergic deficiency occurs during the progression of Alzheimer's disease (AD), resulting in widespread cognitive dysfunction and decline. We evaluated the potential effect of a natural cholinesterase inhibitor, zerumbone, using in vitro target enzyme assays, as well as in silico docking and ADMET (absorption, distribution, metabolism, excretion, and toxicity) simulation. Zerumbone showed a predominant cholinesterase inhibitory property with IC50 values of 2.74 ± 0.48 µM and 4.12 ± 0.42 µM for AChE and BChE, respectively; however, the modes of inhibition were different. Computational docking simulation indicated that Van der Waals interactions between zerumbone and both the cholinesterases were the main forces responsible for its inhibitory effects. Furthermore, zerumbone showed the best physicochemical properties for both bioavailability and blood-brain barrier (BBB) permeability. Together, in the present study, zerumbone was clearly identified as a unique dual AChE and BChE inhibitor with high permeability across the BBB, suggesting a strong potential for its physiological benefits and/or pharmacological e?cacy in the prevention of AD.

SUBMITTER: Hwang J 

PROVIDER: S-EPMC7281973 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biological and Computational Studies for Dual Cholinesterases Inhibitory Effect of Zerumbone.

Hwang Jayeong J   Youn Kumju K   Ji Yeongseon Y   Lee Seonah S   Lim Gyutae G   Lee Jinhyuk J   Ho Chi-Tang CT   Leem Sun-Hee SH   Jun Mira M  

Nutrients 20200425 5


Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) mediate the degradation of acetylcholine (ACh), a primary neurotransmitter in the brain. Cholinergic deficiency occurs during the progression of Alzheimer's disease (AD), resulting in widespread cognitive dysfunction and decline. We evaluated the potential effect of a natural cholinesterase inhibitor, zerumbone, using in vitro target enzyme assays, as well as in silico docking and ADMET (absorption, distribution, metabolism, excretion,  ...[more]

Similar Datasets

| S-EPMC10061512 | biostudies-literature
| S-EPMC6100189 | biostudies-literature
| S-EPMC6084503 | biostudies-literature
| S-EPMC6767256 | biostudies-literature
| S-EPMC8966662 | biostudies-literature
| S-EPMC8122972 | biostudies-literature
| S-EPMC8239243 | biostudies-literature
| S-EPMC8161735 | biostudies-literature
| S-EPMC3963125 | biostudies-literature
| S-EPMC8457019 | biostudies-literature